Mangostenone B

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: Mangostenone B
• 英文别名: 10,22-dihydroxy-7,7,18,18-tetramethyl-11-(3-methylbut-2-enyl)-8,13,17-trioxapentacyclo[12.8.0.03,12.04,9.016,21]docosa-1(22),3,9,11,14,16(21),19-heptaen-2-one
• 化学式: C₂₈H₃₀O₆
• 分子量: 462.5
• InChiKey: CTTYZRNOKDZJRY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  34
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  85.2
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Oral compositions containing extracts of garcinia mangostana l. and related methods
  申请人：Colgate-Palmolive Company

  公开号：EP2689805A1

  公开（公告）日：2014-01-29

  Described herein are compositions comprising a combination of extracts, and methods of preparing and using the same.

  本文描述了包含提取物组合的组合物，以及制备和使用组合物的方法。
• Xanthone-rich plant extracts or compounds therefrom for modulating diseases of the central nervous system and related disorders
  申请人：Deakin University

  公开号：US10568862B2

  公开（公告）日：2020-02-25

  The invention relates to a method of treatment and/or prophylaxis of a disease or disorder of the central nervous system comprising administering to a mammal in need thereof an effective amount of a xanthone-rich plant extract, or a compound derived from a xanthone-rich plant extract. The invention also relates to use of a xanthone-rich plant extract, or a compound derived from a xanthone-rich plant extract, in the preparation of a medicament for the treatment and/or prophylaxis of a disease or disorder of the central nervous system and to a xanthone-rich plant extract, or a compound derived from a xanthone-rich plant extract, for use in the treatment and/or prophylaxis of a disease or disorder of the central nervous system.

  本发明涉及一种治疗和/或预防中枢神经系统疾病或紊乱的方法，包括向需要的哺乳动物施用有效量的富含黄酮的植物提取物或从富含黄酮的植物提取物衍生的化合物。 本发明还涉及富含黄酮的植物提取物或由富含黄酮的植物提取物衍生的化合物在制备治疗和/或预防中枢神经系统疾病或紊乱的药物中的用途，以及富含黄酮的植物提取物或由富含黄酮的植物提取物衍生的化合物在治疗和/或预防中枢神经系统疾病或紊乱中的用途。
• Chemosensory receptor ligand-based therapies
  申请人：Anji Pharma (US) LLC

  公开号：US10610500B2

  公开（公告）日：2020-04-07

  Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.

  本文提供了通过施用包含化感受体配体（如苦味受体配体）的组合物来治疗与化感受体相关的病症（包括糖尿病、肥胖症和其他代谢性疾病、失调或病症）的方法。本文还提供了化学感觉受体配体组合物，包括苦味受体配体组合物，及其用于本发明方法的制备方法。本文还提供了包含二甲双胍及其盐类的组合物和使用方法。
• Pharmaceutical and therapeutic compositions derived from Garcinia mangostana L plant
  申请人：Moffett Alex

  公开号：US20060105069A1

  公开（公告）日：2006-05-18

  The present invention relates to pharmaceutical, therapeutic, nutritional, cosmetic, and dermatological compositions derived from the preicarp (rind) of the Garcinia mangostana L plant and the novel extraction processes used to produce those compositions. Specifically, the present invention relates, in part, to an approximately 0.01% to about 80% mixture of a xanthone-rich mangosteen pericarp (rind) extract in novel combinations for pharmaceutical, cosmetic, therapeutic or dermatological compositions that yield surprising health benefits. Additionally, the present invention relates, in part, to novel extraction processes that result in the production of the novel compositions of the invention.

  本发明涉及药物、治疗、营养、化妆品和皮肤病组合物，这些组合物由芒果树的果皮提取。 果皮 L 植物的前果皮（果皮）中提取的药物、治疗、营养、美容和皮肤病组合物，以及用于生产这些组合物的新型提取工艺。具体而言，本发明部分涉及一种富含氧杂蒽酮的山竹果果皮提取物的约 0.01% 至约 80% 的混合物，该混合物以新颖的组合方式用于制药、美容、治疗或皮肤病组合物，可产生令人惊喜的健康益处。此外，本发明还部分涉及可生产本发明新型组合物的新型提取工艺。
• PHARMACEUTICAL AND THERAPEUTIC COMPOSITIONS DERIVED FROM GARCINIA MANGOSTANA L PLANT
  申请人：Renaissance Herbs, Inc.

  公开号：EP1824442A1

  公开（公告）日：2007-08-29